Skip to main content

Refractory Reflux Esophagitis

1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
EsomeprazolePhase 3Small Molecule1 trial
Active Trials
NCT01669811Completed1,398Est. May 2014
Eisai
EisaiChina - Liaoning
2 programs
rabeprazole sodiumN/A1 trial
E3810PHASE_2_31 trial
Active Trials
NCT01321567Completed2,157Est. Aug 2013
NCT00770913Completed337Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaEsomeprazole
EisaiE3810
Eisairabeprazole sodium

Clinical Trials (3)

Total enrollment: 3,892 patients across 3 trials

NCT01669811AstraZenecaEsomeprazole

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Start: Aug 2012Est. completion: May 20141,398 patients
Phase 3Completed
NCT00770913EisaiE3810

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Start: Oct 2008Est. completion: Mar 2010337 patients
Phase 2/3Completed
NCT01321567Eisairabeprazole sodium

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Start: Jan 2011Est. completion: Aug 20132,157 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.